Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06829784

TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 subjects are expected to be enrolled, with subjects randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

The People's Hospital of Bozhou, Bozhou, Anhui, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sign the informed consent form before the trial to fully understand the purpose, process and possible adverse reactions of the trial;
  • Age 18 ~ 75 years old, gender is not limited;
  • Documented physician diagnosis of asthma at least 12 months prior to Visit 1;
  • Subjects who received high-dose Inhaled Corticosteroids (ICS) in asthma control medications prescribed by their physicians at least 6 months prior to Visit 1;
  • There must be a record of receiving a stable total daily dose of ICS at least 3 months prior to visit 1;
  • There must be a record of the use of other asthma control medications at a stable dose at least 3 months prior to visit 1; For subjects taking maintenance oral hormones, the dose of oral hormones is up to 10mg prednisone per day or 20mg every other day (or equivalent) and must be stable for at least 30 days prior to visit 1 and during treatment.
  • Documented at least 2 asthma exacerbations in the 12 months prior to Visit 1 and no major asthma exacerbation events in the 1 month prior to signing informed.

Exclusion criteria

  • Have a clinically significant lung disease other than asthma;
  • Pre-existing autoimmune disease;
  • A history of known or suspected immunosuppression, including a history of invasive opportunistic infections;
  • Any disease that has not been determined to be stable by the investigator;
  • Cancer history: Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ are eligible to be enrolled in this study if they had completed curative therapy for at least 12 months prior to visit 1. Patients with other malignancies who had completed curative treatment for at least 5 years prior to visit 1 could be enrolled in the study.
  • Current smoker or smoking history ≥10 pack-years (former smokers with smoking history <10 pack-years had quit smoking less than 6 months before interview 1);
  • Other factors determined by the investigator that subjects were not suitable to participate in the study.

Treatment and study plan

TQC2731 injection

Drug

TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.

Placebo

Drug

Placebo without drug substance.

Primary outcomes

  1. Annualized incidence of asthma exacerbations

    Time frame: From the first day of dosing to the completion of 52 weeks of treatment

    Annualized incidence of asthma exacerbations (AAER) during the 52-week treatment period.

Secondary outcomes

  1. The change in forced expiratory volume in 1 second (FEV1)

    Time frame: Week 52 before dosing and before the use of bronchodilators (pre-Bronchodilator (pre-BD) administration)

    At Week 52, the change from baseline in forced expiratory volume in 1 second (FEV1) prior to dosing and before the use of a bronchodilator (pre-BD administration).

  2. Change in total score of standardized asthma quality of life questionnaire

    Time frame: From baseline to week 52

    Change from baseline in standardized asthma quality of life questionnaire (AQLQ(S)+12) total score at week 52. Scores above 5 points indicate a relatively good quality of life, while scores below 3 points suggest a relatively poor quality of life.

  3. Change in Asthma Control Questionnaire-6 (ACQ-6) score

    Time frame: From baseline to week 52

    Mean change from baseline in weekly mean asthma symptom diary score at week 52, , The higher the score, the more severe the asthma symptoms.

  4. Mean change in weekly mean asthma symptom diary score

    Time frame: From baseline to week 52

    Mean change from baseline in weekly mean asthma symptom diary score at week 52

  5. Change in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire score

    Time frame: From baseline to week 52

    Change from baseline in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire score at Week 52, a higher score indicates a better quality of life.

  6. Change in mean rescue medication use, average peak expiratory flow rate (PEF) in the morning and night

    Time frame: From baseline to week 52

    Change from baseline in the average weekly dose of rescue medication and the average peak expiratory flow rate (PEF) per week in the morning and night, respectively

  7. Changes in exhaled nitric oxide Fractional exhaled nitric oxide (FENO) (ppb), peripheral blood eosinophils, total serum Immunoglobulin E (IgE).

    Time frame: From baseline to week 52

    Change from baseline in exhaled nitric oxide FENO (ppb) at week 52.

  8. Changes in peripheral blood eosinophils

    Time frame: From baseline to week 52

    Change from baseline in peripheral blood eosinophils at week 52.

  9. Changes in total serum IgE

    Time frame: From baseline to week 52

    Change from baseline in total serum IgE at week 52.

  10. Time to first asthma exacerbation

    Time frame: Baseline to week 64

    Time to first asthma exacerbation

  11. Proportion of subjects with ≥1 asthma exacerbation

    Time frame: Baseline to week 64

    Proportion of subjects with ≥1 asthma exacerbation

  12. Number of days of glucocorticoid use due to acute exacerbations

    Time frame: Baseline to week 64

    Number of days of glucocorticoid use due to acute exacerbations

  13. Average amount of hormone used per acute exacerbation (prednisone equivalent)

    Time frame: Baseline to week 64

    Average amount of hormone used per acute exacerbation (prednisone equivalent)

  14. Incidence of anti-drug antibodies (ADAs) in subjects

    Time frame: Baseline to week 64

    Immunogenicity: Incidence of anti-drug antibodies (ADAs) in subjects and their titers.

  15. Incidence of neutralizing antibodies(NAB) in subjects

    Time frame: Baseline to week 64

    Immunogenicity: Incidence of neutralizing antibodies (NAB).

Study contacts

Contact information is provided by the study sponsor or research team.

Jinping Zheng, Doctor

CONTACT

[email protected]

18928868238

Qingling Zhang, Doctor

CONTACT

[email protected]

13609068871

Sponsors and collaborators

Lead sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injections in Patients With Poorly Controlled Severe Asthma

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Feb 17, 2025
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.